Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2014, Cilt: 31 Sayı: 1, 31 - 36, 05.06.2014

Mefkure Eraksoy Kadriye Agan Fikri Ak Omer Anlar Belgin Balcı Cavit Boz Yahya Celık Seref Demırkaya Husnu Efendı Muhtesem Gecızlıoglu Dilek Gunal Hulya Aydın Gungor Nihal Isık Egemen Idılman Rana Karabudak Aslı Kurne Munife Neyal Serkan Ozakbas Ozgul Ekmekcı Ozbay Cemal Ozcan Nese Oztekın Musa Ozturk Sabahattin Saıp Aksel Sıva Aysun Soysal Ozlem Taskapılıoglu Murat Terzı Omer Turan Recai Turkoglu Nezih Yucemen Ayse Yuceyar Yasar Zorlu Cunay Ulku Huseyin Dıb Deniz Uren

Öz

Kaynakça

  • Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
  • Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
  • Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
  • Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).

Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

Yıl 2014, Cilt: 31 Sayı: 1, 31 - 36, 05.06.2014

Mefkure Eraksoy Kadriye Agan Fikri Ak Omer Anlar Belgin Balcı Cavit Boz Yahya Celık Seref Demırkaya Husnu Efendı Muhtesem Gecızlıoglu Dilek Gunal Hulya Aydın Gungor Nihal Isık Egemen Idılman Rana Karabudak Aslı Kurne Munife Neyal Serkan Ozakbas Ozgul Ekmekcı Ozbay Cemal Ozcan Nese Oztekın Musa Ozturk Sabahattin Saıp Aksel Sıva Aysun Soysal Ozlem Taskapılıoglu Murat Terzı Omer Turan Recai Turkoglu Nezih Yucemen Ayse Yuceyar Yasar Zorlu Cunay Ulku Huseyin Dıb Deniz Uren

Öz

Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and compared with demographic and therapy related factors. Serum samples were collected from 308 RRMS patients at 24 centers, and tested by STRATIFY JCV assay for the presence of anti-JCV antibodies. Also, demographic, disease and treatment data were collected at the same time and were used for analysis of associations with seropositivity. The prevalence of anti-JCV antibodies was observed to be 68.2%, which is higher than most countries. There was a trend in terms of higher seroprevalence of antibodies in older patients, and male patients. There was no association with previous
natalizumab use, but there was a significantly higher seroprevalence in patients who used immunosuppressant therapies (p<0.05). JCV prevalence rate is observed to be
high in Turkish MS patients, therefore it would be beneficial to use this marker as a risk stratification tool in clinical decision making.

Anahtar Kelimeler

John Cunningham Virus Multiple Sclerosis Natalizumab Turkey

Kaynakça

  • Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
  • Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
  • Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
  • Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).
Toplam 4 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Basic Medical Sciences
Yazarlar

Mefkure Eraksoy

Kadriye Agan

Fikri Ak

Omer Anlar

Belgin Balcı

Cavit Boz

Yahya Celık

Seref Demırkaya

Husnu Efendı

Muhtesem Gecızlıoglu

Dilek Gunal

Hulya Aydın Gungor

Nihal Isık

Egemen Idılman

Rana Karabudak

Aslı Kurne

Munife Neyal

Serkan Ozakbas

Ozgul Ekmekcı Ozbay

Cemal Ozcan

Nese Oztekın

Musa Ozturk

Sabahattin Saıp

Aksel Sıva

Aysun Soysal

Ozlem Taskapılıoglu

Murat Terzı

Omer Turan

Recai Turkoglu

Nezih Yucemen

Ayse Yuceyar

Yasar Zorlu

Cunay Ulku

Huseyin Dıb

Deniz Uren

Yayımlanma Tarihi 5 Haziran 2014
Gönderilme Tarihi 16 Aralık 2013
Yayımlandığı Sayı Yıl 2014 Cilt: 31 Sayı: 1

Kaynak Göster

APA Eraksoy, M., Agan, K., Ak, F., Anlar, O., vd. (2014). Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Deneysel Ve Klinik Tıp Dergisi, 31(1), 31-36.
AMA Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. Haziran 2014;31(1):31-36.
Chicago Eraksoy, Mefkure, Kadriye Agan, Fikri Ak, Omer Anlar, Belgin Balcı, Cavit Boz, Yahya Celık, Seref Demırkaya, Husnu Efendı, Muhtesem Gecızlıoglu, Dilek Gunal, Hulya Aydın Gungor, Nihal Isık, Egemen Idılman, Rana Karabudak, Aslı Kurne, Munife Neyal, Serkan Ozakbas, Ozgul Ekmekcı Ozbay, Cemal Ozcan, Nese Oztekın, Musa Ozturk, Sabahattin Saıp, Aksel Sıva, Aysun Soysal, Ozlem Taskapılıoglu, Murat Terzı, Omer Turan, Recai Turkoglu, Nezih Yucemen, Ayse Yuceyar, Yasar Zorlu, Cunay Ulku, Huseyin Dıb, ve Deniz Uren. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel Ve Klinik Tıp Dergisi 31, sy. 1 (Haziran 2014): 31-36.
EndNote Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D (01 Haziran 2014) Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Deneysel ve Klinik Tıp Dergisi 31 1 31–36.
IEEE M. Eraksoy, “Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey”, J. Exp. Clin. Med., c. 31, sy. 1, ss. 31–36, 2014.
ISNAD Eraksoy, Mefkure vd. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel ve Klinik Tıp Dergisi 31/1 (Haziran 2014), 31-36.
JAMA Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31:31–36.
MLA Eraksoy, Mefkure vd. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel Ve Klinik Tıp Dergisi, c. 31, sy. 1, 2014, ss. 31-36.
Vancouver Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31(1):31-6.
 Kapak Resmi İndir

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.